Elan Spin-Out Prothena Awaits First Clinical Data As Stock Price Climbs
This article was originally published in The Pink Sheet Daily
Executive Summary
A year after Prothena spun out of Elan as an independent, publicly traded biotech, it has three actively advancing pipeline programs involving compounds with new mechanisms of action, including a Phase I trial underway for an amyloidosis therapy.